肾移植受者用药依从性与癌症风险增加相关:一项队列研究
该队列研究纳入195例同意接受电子监测的肾移植受者,监测移植后6个月内免疫抑制剂依从性,中位随访10.1年。按依从性三分位分组后,10年累积癌症发生率最高依从组为59.4%,中间组36.1%,最低组38.1%(P=0.006);排除非黑色素细胞皮肤癌后最高依从组癌症发生率仍显著更高(P=0.002)。结论提示需个体化免疫抑制方案以平衡排斥与癌症等并发症风险。
要点
- 移植后6个月免疫抑制剂依从性最高组10年累积癌症发生率为59.4%。
- 最高依从组癌症风险显著高于中、低依从组(P=0.006)。
- 排除非黑色素细胞皮肤癌后,最高依从组癌症发生率仍显著更高(P=0.002)。
核心结论
- 移植后免疫抑制剂依从性极高与癌症风险增加相关,提示需个体化免疫抑制以平衡排斥与过度免疫抑制并发症。
研究设计与样本
- 1998年8月至2006年8月纳入195例同意电子监测的肾移植受者,监测移植后6个月免疫抑制剂依从性,中位随访10.1年。
主要发现
- 按平均定量依从性三分位分组:最高组>97.9%,中间组91–97.8%,最低组<91%。
- 10年估计累积癌症发生率:最高依从组59.4%,中间组36.1%,最低组38.1%(P=0.006)。
- 排除非黑色素细胞皮肤癌后,最高依从组癌症发生率仍显著更高(P=0.002)。
关键数值与推荐
- 依从性三分位阈值:最高>97.9%,中间91–97.8%,最低<91%。
- 10年累积癌症发生率最高组59.4%、中间组36.1%、最低组38.1%(P=0.006)。
- 排除非黑色素细胞皮肤癌后最高依从组癌症发生率仍显著更高(P=0.002)。
临床怎么用
- 对免疫抑制剂依从性极高的肾移植受者,应关注过度免疫抑制相关癌症风险,个体化调整免疫抑制方案。
局限性
- 样本量195例,单中心队列,依从性仅监测移植后6个月,癌症发生率为估计值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nonadherence to posttransplant immunosuppressive medication is associated with increased rates of rejection and graft loss, yet it is unknown to what degree ideal adherence is associated with the sequelae of overimmunosuppression. Specifically, we questioned whether excellent adherence increased the posttransplant cancer risk. METHODS: Between August 1998 and August 2006, 195 consenting kidney transplant recipients had electronic monitoring of theirimmunosuppressive medication adherence. RESULTS: Based on their average quantitative adherence to a single immunosuppressant drug over the first 6 months posttransplant, recipients were grouped into adherence tertiles (highest, >97.9% adherence; middle, 91-97.8%; lowest, <91%). The cumulative incidence of cancer was calculated for patients in each tertile, treating death as a competing risk. The association between adherence and cancer rate was calculated after adjusting for recipient risk factors, using a competing risk proportional hazards model. The median duration of follow-up was 10.1 years. The 10-year estimated cumulative cancer incidence was 59.4% in the most adherent, 36.1% in the middle group and 38.1% in the least adherent group (P = 0.006). Excluding nonmelanocytic skin cancers, cancer incidence remained significantly higher in the highest adherence group (P = 0.002). CONCLUSIONS: These data provide additional support for the need to individualize immunosuppression to minimize both rejection and immunosuppressive drug-related complications including cancer.
引用
- Yadav K, Vock DM, Matas AJ, et al. Medication adherence is associated with an increased risk of cancer in kidney transplant recipients: a cohort study. Nephrol Dial Transplant. 2019. PMID: 30102328. doi:10.1093/ndt/gfy210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。